AngloGold Ashanti Q1 31 March 2026 Earnings Release and Dividend Declaration May 8, 2026 AngloGold Ashanti delivers record free cash flow* of $1.2bn and EBITDA*(4) of $2.3bn • Gold production(1)(2) +1% • Net cash*(4) of $868m • Q1 2026 interim dividend of $585m, or 116 cps • Proposed $2.0bn share repurchase programme announced
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate
Algoma Central Corporation Reports Financial Results for the 2026 First Quarter May 7, 2026 Focused fleet growth, strategic opportunities, and built-in adaptability across domestic and international operations drove a resilient first quarter
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results May 7, 2026 Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026
Arm Holdings plc Reports Results for the Fourth Quarter and Fiscal Year Ended 2026 May 6, 2026 Arm Holdings plc (NASDAQ: ARM), the company that is building the future of computing, has today published a letter to its shareholders containing the company’s results for its fourth quarter and fiscal year ended March 31, 2026. The letter is available on its investor relations website (https://investors.arm.com/financials/quarterly-annual-results). The shareholder letter will also be furnished to [...]
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026 May 6, 2026 Compass management will host a conference call at 8:00 am ET (1:00 pm UK)
IFF Reports First Quarter 2026 Results May 5, 2026 Delivered solid top and bottom line Q1 results Progressing disciplined sale process for Food Ingredients business Reaffirms Full Year 2026 Financial Guidance
Logitech Announces Q4 and Full Fiscal Year 2026 Results May 5, 2026 Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering
IGI Reports First Quarter of 2026 Unaudited Financial Results May 5, 2026 International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today reported financial results for the first quarter of 2026. Highlights for the first quarter of 2026 include: (in millions of U.S. Dollars, except percentages and per share information) Quarter Ended March 31, 2026 2025 Gross written premiums $197.2 $206.5 Net premiums [...]
Alkermes plc Reports First Quarter 2026 Financial Results May 5, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. [...]